As More Labs Introduce Array-based Prenatal Dx Tests, Debate Rages over Indication, Platform Choice | GenomeWeb

Cytogeneticists are increasingly adopting chromosomal microarrays for prenatal diagnostics, but have not yet reached a consensus when it comes to what kinds of cases should undergo array-based screening and which platform is best to use.

In addition, findings of unknown clinical significance continue to slow the uptake of the technology for prenatal testing, as some in the cytogenetics community hope that time, and experience, will put to rest most of the questions about the new technology and the data it provides.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.